nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—UGT1A1—lung cancer	0.264	0.658	CbGaD
Naproxen—PTGS2—lung cancer	0.0725	0.181	CbGaD
Naproxen—AKR1C3—Doxorubicin—lung cancer	0.0653	0.183	CbGbCtD
Naproxen—ALB—lung cancer	0.0646	0.161	CbGaD
Naproxen—UGT1A1—Erlotinib—lung cancer	0.0357	0.1	CbGbCtD
Naproxen—UGT1A1—Irinotecan—lung cancer	0.0322	0.0904	CbGbCtD
Naproxen—UGT1A1—Etoposide—lung cancer	0.0258	0.0724	CbGbCtD
Naproxen—ALB—Gefitinib—lung cancer	0.0229	0.0642	CbGbCtD
Naproxen—PTGS2—Cisplatin—lung cancer	0.0158	0.0443	CbGbCtD
Naproxen—PTGS2—Etoposide—lung cancer	0.0155	0.0435	CbGbCtD
Naproxen—ALB—Erlotinib—lung cancer	0.0135	0.038	CbGbCtD
Naproxen—PTGS1—Etoposide—lung cancer	0.0131	0.0368	CbGbCtD
Naproxen—SLCO1A2—Methotrexate—lung cancer	0.0125	0.0351	CbGbCtD
Naproxen—CYP2C9—Gefitinib—lung cancer	0.0123	0.0346	CbGbCtD
Naproxen—ALB—Irinotecan—lung cancer	0.0122	0.0343	CbGbCtD
Naproxen—CYP2C9—Teniposide—lung cancer	0.012	0.0335	CbGbCtD
Naproxen—CYP2C8—Erlotinib—lung cancer	0.0105	0.0293	CbGbCtD
Naproxen—CYP2C8—Paclitaxel—lung cancer	0.00957	0.0268	CbGbCtD
Naproxen—CYP1A2—Erlotinib—lung cancer	0.00809	0.0227	CbGbCtD
Naproxen—SLC22A6—Methotrexate—lung cancer	0.00759	0.0213	CbGbCtD
Naproxen—CYP2C8—Etoposide—lung cancer	0.00756	0.0212	CbGbCtD
Naproxen—CYP2C9—Paclitaxel—lung cancer	0.00668	0.0187	CbGbCtD
Naproxen—ALB—Methotrexate—lung cancer	0.00647	0.0181	CbGbCtD
Naproxen—CYP1A2—Etoposide—lung cancer	0.00585	0.0164	CbGbCtD
Naproxen—CYP2C9—Cisplatin—lung cancer	0.00537	0.0151	CbGbCtD
Naproxen—AKR1C3—Podofilox—Teniposide—lung cancer	0.000941	0.307	CbGdCrCtD
Naproxen—AKR1C3—Vincristine—Vinorelbine—lung cancer	0.000599	0.196	CbGdCrCtD
Naproxen—AKR1C3—Podofilox—Etoposide—lung cancer	0.000559	0.183	CbGdCrCtD
Naproxen—AKR1C3—Vinblastine—Vinorelbine—lung cancer	0.000482	0.157	CbGdCrCtD
Naproxen—AKR1C3—Vincristine—Vinblastine—lung cancer	0.000479	0.156	CbGdCrCtD
Naproxen—Suprofen—UGT1A1—lung cancer	0.000459	0.124	CrCbGaD
Naproxen—Indomethacin—ABCC3—lung cancer	0.000338	0.0916	CrCbGaD
Naproxen—Indomethacin—UGT1A1—lung cancer	0.000292	0.0791	CrCbGaD
Naproxen—Indomethacin—CXCL8—lung cancer	0.000275	0.0746	CrCbGaD
Naproxen—Flurbiprofen—UGT1A1—lung cancer	0.000258	0.07	CrCbGaD
Naproxen—Ibuprofen—UGT1A1—lung cancer	0.00023	0.0623	CrCbGaD
Naproxen—Ketoprofen—CXCL8—lung cancer	0.00022	0.0597	CrCbGaD
Naproxen—Ibuprofen—CXCL8—lung cancer	0.000217	0.0588	CrCbGaD
Naproxen—Nabumetone—PTGS2—lung cancer	0.000214	0.0581	CrCbGaD
Naproxen—Carprofen—PTGS2—lung cancer	0.000204	0.0554	CrCbGaD
Naproxen—ALB—mammary gland—lung cancer	0.000176	0.0913	CbGeAlD
Naproxen—AKR1C3—bronchus—lung cancer	0.000155	0.0806	CbGeAlD
Naproxen—AKR1C3—trachea—lung cancer	0.000139	0.0724	CbGeAlD
Naproxen—AKR1C3—cardiac atrium—lung cancer	0.000131	0.068	CbGeAlD
Naproxen—Suprofen—PTGS2—lung cancer	0.000126	0.0342	CrCbGaD
Naproxen—CYP2C8—mammary gland—lung cancer	0.000124	0.0641	CbGeAlD
Naproxen—AKR1C3—bone marrow—lung cancer	0.000111	0.0574	CbGeAlD
Naproxen—CYP2C9—mammary gland—lung cancer	0.00011	0.057	CbGeAlD
Naproxen—Fenoprofen—PTGS2—lung cancer	0.000109	0.0295	CrCbGaD
Naproxen—AKR1C3—lung—lung cancer	0.0001	0.052	CbGeAlD
Naproxen—Fenoprofen—ALB—lung cancer	9.69e-05	0.0263	CrCbGaD
Naproxen—Indomethacin—PTGS2—lung cancer	8.03e-05	0.0218	CrCbGaD
Naproxen—CYP1A2—respiratory system—lung cancer	7.7e-05	0.04	CbGeAlD
Naproxen—Indomethacin—ALB—lung cancer	7.15e-05	0.0194	CrCbGaD
Naproxen—Flurbiprofen—PTGS2—lung cancer	7.1e-05	0.0192	CrCbGaD
Naproxen—AKR1C3—lymph node—lung cancer	6.85e-05	0.0356	CbGeAlD
Naproxen—Indomethacin—ABCB1—lung cancer	6.83e-05	0.0185	CrCbGaD
Naproxen—PTGS1—respiratory system—lung cancer	6.68e-05	0.0347	CbGeAlD
Naproxen—Ketoprofen—PTGS2—lung cancer	6.42e-05	0.0174	CrCbGaD
Naproxen—PTGS2—respiratory system—lung cancer	6.38e-05	0.0331	CbGeAlD
Naproxen—Flurbiprofen—ALB—lung cancer	6.32e-05	0.0172	CrCbGaD
Naproxen—Ibuprofen—PTGS2—lung cancer	6.32e-05	0.0171	CrCbGaD
Naproxen—SLCO1A2—lung—lung cancer	6.26e-05	0.0325	CbGeAlD
Naproxen—Ketoprofen—ALB—lung cancer	5.72e-05	0.0155	CrCbGaD
Naproxen—Ibuprofen—ALB—lung cancer	5.63e-05	0.0153	CrCbGaD
Naproxen—PTGS1—epithelium—lung cancer	5.58e-05	0.029	CbGeAlD
Naproxen—Ibuprofen—ABCB1—lung cancer	5.38e-05	0.0146	CrCbGaD
Naproxen—PTGS2—epithelium—lung cancer	5.33e-05	0.0277	CbGeAlD
Naproxen—PTGS2—bronchus—lung cancer	5.25e-05	0.0273	CbGeAlD
Naproxen—PTGS1—trachea—lung cancer	4.93e-05	0.0256	CbGeAlD
Naproxen—PTGS2—trachea—lung cancer	4.72e-05	0.0245	CbGeAlD
Naproxen—PTGS1—cardiac atrium—lung cancer	4.63e-05	0.0241	CbGeAlD
Naproxen—ALB—lymph node—lung cancer	4.25e-05	0.0221	CbGeAlD
Naproxen—CYP1A2—lung—lung cancer	4.09e-05	0.0212	CbGeAlD
Naproxen—PTGS2—bone marrow—lung cancer	3.74e-05	0.0194	CbGeAlD
Naproxen—PTGS1—lung—lung cancer	3.54e-05	0.0184	CbGeAlD
Naproxen—Urinary tract disorder—Methotrexate—lung cancer	3.5e-05	0.000232	CcSEcCtD
Naproxen—Photosensitivity reaction—Doxorubicin—lung cancer	3.5e-05	0.000232	CcSEcCtD
Naproxen—Anaphylactic shock—Docetaxel—lung cancer	3.49e-05	0.000231	CcSEcCtD
Naproxen—Oedema—Docetaxel—lung cancer	3.49e-05	0.000231	CcSEcCtD
Naproxen—Pruritus—Gemcitabine—lung cancer	3.48e-05	0.000231	CcSEcCtD
Naproxen—Urethral disorder—Methotrexate—lung cancer	3.47e-05	0.00023	CcSEcCtD
Naproxen—Infection—Docetaxel—lung cancer	3.47e-05	0.00023	CcSEcCtD
Naproxen—Weight decreased—Doxorubicin—lung cancer	3.47e-05	0.00023	CcSEcCtD
Naproxen—Feeling abnormal—Etoposide—lung cancer	3.46e-05	0.000229	CcSEcCtD
Naproxen—Hyperglycaemia—Doxorubicin—lung cancer	3.46e-05	0.000229	CcSEcCtD
Naproxen—Diarrhoea—Irinotecan—lung cancer	3.46e-05	0.000229	CcSEcCtD
Naproxen—Pneumonia—Doxorubicin—lung cancer	3.44e-05	0.000228	CcSEcCtD
Naproxen—Gastrointestinal pain—Etoposide—lung cancer	3.44e-05	0.000228	CcSEcCtD
Naproxen—Shock—Docetaxel—lung cancer	3.44e-05	0.000227	CcSEcCtD
Naproxen—Nervous system disorder—Docetaxel—lung cancer	3.42e-05	0.000227	CcSEcCtD
Naproxen—Thrombocytopenia—Docetaxel—lung cancer	3.42e-05	0.000226	CcSEcCtD
Naproxen—Drowsiness—Doxorubicin—lung cancer	3.42e-05	0.000226	CcSEcCtD
Naproxen—Visual impairment—Methotrexate—lung cancer	3.41e-05	0.000226	CcSEcCtD
Naproxen—Tachycardia—Docetaxel—lung cancer	3.41e-05	0.000226	CcSEcCtD
Naproxen—Feeling abnormal—Paclitaxel—lung cancer	3.39e-05	0.000225	CcSEcCtD
Naproxen—Skin disorder—Docetaxel—lung cancer	3.39e-05	0.000225	CcSEcCtD
Naproxen—PTGS2—lung—lung cancer	3.39e-05	0.0176	CbGeAlD
Naproxen—Stevens-Johnson syndrome—Doxorubicin—lung cancer	3.39e-05	0.000224	CcSEcCtD
Naproxen—Hypersensitivity—Cisplatin—lung cancer	3.38e-05	0.000224	CcSEcCtD
Naproxen—Gastrointestinal pain—Paclitaxel—lung cancer	3.37e-05	0.000223	CcSEcCtD
Naproxen—Diarrhoea—Gemcitabine—lung cancer	3.37e-05	0.000223	CcSEcCtD
Naproxen—Renal failure—Doxorubicin—lung cancer	3.36e-05	0.000222	CcSEcCtD
Naproxen—Erythema multiforme—Methotrexate—lung cancer	3.35e-05	0.000222	CcSEcCtD
Naproxen—Neuropathy peripheral—Doxorubicin—lung cancer	3.35e-05	0.000222	CcSEcCtD
Naproxen—Dizziness—Irinotecan—lung cancer	3.34e-05	0.000221	CcSEcCtD
Naproxen—Urticaria—Etoposide—lung cancer	3.34e-05	0.000221	CcSEcCtD
Naproxen—Stomatitis—Doxorubicin—lung cancer	3.33e-05	0.000221	CcSEcCtD
Naproxen—Jaundice—Doxorubicin—lung cancer	3.33e-05	0.000221	CcSEcCtD
Naproxen—Anorexia—Docetaxel—lung cancer	3.33e-05	0.00022	CcSEcCtD
Naproxen—Body temperature increased—Etoposide—lung cancer	3.32e-05	0.00022	CcSEcCtD
Naproxen—Abdominal pain—Etoposide—lung cancer	3.32e-05	0.00022	CcSEcCtD
Naproxen—Urinary tract infection—Doxorubicin—lung cancer	3.32e-05	0.00022	CcSEcCtD
Naproxen—Conjunctivitis—Doxorubicin—lung cancer	3.32e-05	0.00022	CcSEcCtD
Naproxen—Eye disorder—Methotrexate—lung cancer	3.31e-05	0.000219	CcSEcCtD
Naproxen—Tinnitus—Methotrexate—lung cancer	3.3e-05	0.000219	CcSEcCtD
Naproxen—Asthenia—Cisplatin—lung cancer	3.29e-05	0.000218	CcSEcCtD
Naproxen—Cardiac disorder—Methotrexate—lung cancer	3.29e-05	0.000218	CcSEcCtD
Naproxen—Sweating—Doxorubicin—lung cancer	3.28e-05	0.000217	CcSEcCtD
Naproxen—Urticaria—Paclitaxel—lung cancer	3.27e-05	0.000217	CcSEcCtD
Naproxen—Hypotension—Docetaxel—lung cancer	3.26e-05	0.000216	CcSEcCtD
Naproxen—Haematuria—Doxorubicin—lung cancer	3.26e-05	0.000216	CcSEcCtD
Naproxen—Body temperature increased—Paclitaxel—lung cancer	3.26e-05	0.000216	CcSEcCtD
Naproxen—Abdominal pain—Paclitaxel—lung cancer	3.26e-05	0.000216	CcSEcCtD
Naproxen—Hepatobiliary disease—Doxorubicin—lung cancer	3.23e-05	0.000214	CcSEcCtD
Naproxen—Epistaxis—Doxorubicin—lung cancer	3.22e-05	0.000213	CcSEcCtD
Naproxen—Angiopathy—Methotrexate—lung cancer	3.21e-05	0.000213	CcSEcCtD
Naproxen—Vomiting—Irinotecan—lung cancer	3.21e-05	0.000213	CcSEcCtD
Naproxen—Sinusitis—Doxorubicin—lung cancer	3.21e-05	0.000212	CcSEcCtD
Naproxen—Immune system disorder—Methotrexate—lung cancer	3.2e-05	0.000212	CcSEcCtD
Naproxen—Mediastinal disorder—Methotrexate—lung cancer	3.19e-05	0.000211	CcSEcCtD
Naproxen—Agranulocytosis—Doxorubicin—lung cancer	3.19e-05	0.000211	CcSEcCtD
Naproxen—Rash—Irinotecan—lung cancer	3.18e-05	0.000211	CcSEcCtD
Naproxen—Dermatitis—Irinotecan—lung cancer	3.18e-05	0.000211	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Docetaxel—lung cancer	3.18e-05	0.000211	CcSEcCtD
Naproxen—Chills—Methotrexate—lung cancer	3.18e-05	0.00021	CcSEcCtD
Naproxen—Headache—Irinotecan—lung cancer	3.16e-05	0.00021	CcSEcCtD
Naproxen—Insomnia—Docetaxel—lung cancer	3.16e-05	0.000209	CcSEcCtD
Naproxen—Diarrhoea—Cisplatin—lung cancer	3.14e-05	0.000208	CcSEcCtD
Naproxen—Paraesthesia—Docetaxel—lung cancer	3.14e-05	0.000208	CcSEcCtD
Naproxen—Alopecia—Methotrexate—lung cancer	3.13e-05	0.000207	CcSEcCtD
Naproxen—Vomiting—Gemcitabine—lung cancer	3.13e-05	0.000207	CcSEcCtD
Naproxen—Dyspnoea—Docetaxel—lung cancer	3.11e-05	0.000206	CcSEcCtD
Naproxen—Somnolence—Docetaxel—lung cancer	3.1e-05	0.000206	CcSEcCtD
Naproxen—Mental disorder—Methotrexate—lung cancer	3.1e-05	0.000205	CcSEcCtD
Naproxen—Rash—Gemcitabine—lung cancer	3.1e-05	0.000205	CcSEcCtD
Naproxen—Dermatitis—Gemcitabine—lung cancer	3.1e-05	0.000205	CcSEcCtD
Naproxen—Hypersensitivity—Etoposide—lung cancer	3.1e-05	0.000205	CcSEcCtD
Naproxen—Erythema—Methotrexate—lung cancer	3.08e-05	0.000204	CcSEcCtD
Naproxen—Malnutrition—Methotrexate—lung cancer	3.08e-05	0.000204	CcSEcCtD
Naproxen—Haemoglobin—Doxorubicin—lung cancer	3.08e-05	0.000204	CcSEcCtD
Naproxen—Headache—Gemcitabine—lung cancer	3.08e-05	0.000204	CcSEcCtD
Naproxen—Rhinitis—Doxorubicin—lung cancer	3.08e-05	0.000204	CcSEcCtD
Naproxen—Dyspepsia—Docetaxel—lung cancer	3.07e-05	0.000204	CcSEcCtD
Naproxen—Haemorrhage—Doxorubicin—lung cancer	3.07e-05	0.000203	CcSEcCtD
Naproxen—Hepatitis—Doxorubicin—lung cancer	3.07e-05	0.000203	CcSEcCtD
Naproxen—Pharyngitis—Doxorubicin—lung cancer	3.04e-05	0.000202	CcSEcCtD
Naproxen—Decreased appetite—Docetaxel—lung cancer	3.04e-05	0.000201	CcSEcCtD
Naproxen—Hypersensitivity—Paclitaxel—lung cancer	3.04e-05	0.000201	CcSEcCtD
Naproxen—Urinary tract disorder—Doxorubicin—lung cancer	3.03e-05	0.000201	CcSEcCtD
Naproxen—Oedema peripheral—Doxorubicin—lung cancer	3.02e-05	0.0002	CcSEcCtD
Naproxen—Gastrointestinal disorder—Docetaxel—lung cancer	3.01e-05	0.0002	CcSEcCtD
Naproxen—Asthenia—Etoposide—lung cancer	3.01e-05	0.0002	CcSEcCtD
Naproxen—Connective tissue disorder—Doxorubicin—lung cancer	3.01e-05	0.0002	CcSEcCtD
Naproxen—Fatigue—Docetaxel—lung cancer	3.01e-05	0.000199	CcSEcCtD
Naproxen—Urethral disorder—Doxorubicin—lung cancer	3.01e-05	0.000199	CcSEcCtD
Naproxen—Nausea—Irinotecan—lung cancer	3e-05	0.000199	CcSEcCtD
Naproxen—Pain—Docetaxel—lung cancer	2.99e-05	0.000198	CcSEcCtD
Naproxen—Constipation—Docetaxel—lung cancer	2.99e-05	0.000198	CcSEcCtD
Naproxen—Pruritus—Etoposide—lung cancer	2.97e-05	0.000197	CcSEcCtD
Naproxen—Visual impairment—Doxorubicin—lung cancer	2.96e-05	0.000196	CcSEcCtD
Naproxen—Asthenia—Paclitaxel—lung cancer	2.96e-05	0.000196	CcSEcCtD
Naproxen—Nausea—Gemcitabine—lung cancer	2.92e-05	0.000194	CcSEcCtD
Naproxen—Vomiting—Cisplatin—lung cancer	2.92e-05	0.000193	CcSEcCtD
Naproxen—Pruritus—Paclitaxel—lung cancer	2.91e-05	0.000193	CcSEcCtD
Naproxen—Vision blurred—Methotrexate—lung cancer	2.91e-05	0.000192	CcSEcCtD
Naproxen—Erythema multiforme—Doxorubicin—lung cancer	2.9e-05	0.000192	CcSEcCtD
Naproxen—Rash—Cisplatin—lung cancer	2.89e-05	0.000191	CcSEcCtD
Naproxen—Dermatitis—Cisplatin—lung cancer	2.89e-05	0.000191	CcSEcCtD
Naproxen—Feeling abnormal—Docetaxel—lung cancer	2.88e-05	0.000191	CcSEcCtD
Naproxen—Diarrhoea—Etoposide—lung cancer	2.87e-05	0.00019	CcSEcCtD
Naproxen—Eye disorder—Doxorubicin—lung cancer	2.87e-05	0.00019	CcSEcCtD
Naproxen—Ill-defined disorder—Methotrexate—lung cancer	2.86e-05	0.000189	CcSEcCtD
Naproxen—Tinnitus—Doxorubicin—lung cancer	2.86e-05	0.000189	CcSEcCtD
Naproxen—Gastrointestinal pain—Docetaxel—lung cancer	2.86e-05	0.000189	CcSEcCtD
Naproxen—Anaemia—Methotrexate—lung cancer	2.85e-05	0.000189	CcSEcCtD
Naproxen—Cardiac disorder—Doxorubicin—lung cancer	2.85e-05	0.000188	CcSEcCtD
Naproxen—Diarrhoea—Paclitaxel—lung cancer	2.82e-05	0.000187	CcSEcCtD
Naproxen—Angiopathy—Doxorubicin—lung cancer	2.78e-05	0.000184	CcSEcCtD
Naproxen—Malaise—Methotrexate—lung cancer	2.78e-05	0.000184	CcSEcCtD
Naproxen—Dizziness—Etoposide—lung cancer	2.78e-05	0.000184	CcSEcCtD
Naproxen—Immune system disorder—Doxorubicin—lung cancer	2.77e-05	0.000183	CcSEcCtD
Naproxen—Vertigo—Methotrexate—lung cancer	2.77e-05	0.000183	CcSEcCtD
Naproxen—Mediastinal disorder—Doxorubicin—lung cancer	2.76e-05	0.000183	CcSEcCtD
Naproxen—Abdominal pain—Docetaxel—lung cancer	2.76e-05	0.000183	CcSEcCtD
Naproxen—Body temperature increased—Docetaxel—lung cancer	2.76e-05	0.000183	CcSEcCtD
Naproxen—Leukopenia—Methotrexate—lung cancer	2.76e-05	0.000183	CcSEcCtD
Naproxen—Chills—Doxorubicin—lung cancer	2.75e-05	0.000182	CcSEcCtD
Naproxen—Arrhythmia—Doxorubicin—lung cancer	2.74e-05	0.000181	CcSEcCtD
Naproxen—Dizziness—Paclitaxel—lung cancer	2.72e-05	0.00018	CcSEcCtD
Naproxen—Nausea—Cisplatin—lung cancer	2.72e-05	0.00018	CcSEcCtD
Naproxen—Alopecia—Doxorubicin—lung cancer	2.71e-05	0.000179	CcSEcCtD
Naproxen—Cough—Methotrexate—lung cancer	2.69e-05	0.000178	CcSEcCtD
Naproxen—Mental disorder—Doxorubicin—lung cancer	2.69e-05	0.000178	CcSEcCtD
Naproxen—Convulsion—Methotrexate—lung cancer	2.67e-05	0.000177	CcSEcCtD
Naproxen—Vomiting—Etoposide—lung cancer	2.67e-05	0.000177	CcSEcCtD
Naproxen—Malnutrition—Doxorubicin—lung cancer	2.67e-05	0.000177	CcSEcCtD
Naproxen—Erythema—Doxorubicin—lung cancer	2.67e-05	0.000177	CcSEcCtD
Naproxen—Rash—Etoposide—lung cancer	2.65e-05	0.000175	CcSEcCtD
Naproxen—Dermatitis—Etoposide—lung cancer	2.65e-05	0.000175	CcSEcCtD
Naproxen—Headache—Etoposide—lung cancer	2.63e-05	0.000174	CcSEcCtD
Naproxen—Flatulence—Doxorubicin—lung cancer	2.63e-05	0.000174	CcSEcCtD
Naproxen—Myalgia—Methotrexate—lung cancer	2.63e-05	0.000174	CcSEcCtD
Naproxen—Arthralgia—Methotrexate—lung cancer	2.63e-05	0.000174	CcSEcCtD
Naproxen—Chest pain—Methotrexate—lung cancer	2.63e-05	0.000174	CcSEcCtD
Naproxen—Tension—Doxorubicin—lung cancer	2.62e-05	0.000174	CcSEcCtD
Naproxen—Vomiting—Paclitaxel—lung cancer	2.62e-05	0.000173	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	2.61e-05	0.000173	CcSEcCtD
Naproxen—Rash—Paclitaxel—lung cancer	2.6e-05	0.000172	CcSEcCtD
Naproxen—Dermatitis—Paclitaxel—lung cancer	2.6e-05	0.000172	CcSEcCtD
Naproxen—Discomfort—Methotrexate—lung cancer	2.59e-05	0.000172	CcSEcCtD
Naproxen—Nervousness—Doxorubicin—lung cancer	2.59e-05	0.000172	CcSEcCtD
Naproxen—Headache—Paclitaxel—lung cancer	2.58e-05	0.000171	CcSEcCtD
Naproxen—Hypersensitivity—Docetaxel—lung cancer	2.57e-05	0.00017	CcSEcCtD
Naproxen—Muscle spasms—Doxorubicin—lung cancer	2.57e-05	0.00017	CcSEcCtD
Naproxen—Confusional state—Methotrexate—lung cancer	2.54e-05	0.000168	CcSEcCtD
Naproxen—Anaphylactic shock—Methotrexate—lung cancer	2.52e-05	0.000167	CcSEcCtD
Naproxen—Vision blurred—Doxorubicin—lung cancer	2.52e-05	0.000167	CcSEcCtD
Naproxen—Asthenia—Docetaxel—lung cancer	2.51e-05	0.000166	CcSEcCtD
Naproxen—Infection—Methotrexate—lung cancer	2.5e-05	0.000166	CcSEcCtD
Naproxen—Nausea—Etoposide—lung cancer	2.5e-05	0.000165	CcSEcCtD
Naproxen—Ill-defined disorder—Doxorubicin—lung cancer	2.48e-05	0.000164	CcSEcCtD
Naproxen—Pruritus—Docetaxel—lung cancer	2.47e-05	0.000164	CcSEcCtD
Naproxen—Nervous system disorder—Methotrexate—lung cancer	2.47e-05	0.000163	CcSEcCtD
Naproxen—Anaemia—Doxorubicin—lung cancer	2.47e-05	0.000163	CcSEcCtD
Naproxen—Thrombocytopenia—Methotrexate—lung cancer	2.46e-05	0.000163	CcSEcCtD
Naproxen—Nausea—Paclitaxel—lung cancer	2.45e-05	0.000162	CcSEcCtD
Naproxen—Skin disorder—Methotrexate—lung cancer	2.44e-05	0.000162	CcSEcCtD
Naproxen—Hyperhidrosis—Methotrexate—lung cancer	2.43e-05	0.000161	CcSEcCtD
Naproxen—PTGS1—lymph node—lung cancer	2.42e-05	0.0126	CbGeAlD
Naproxen—Malaise—Doxorubicin—lung cancer	2.41e-05	0.000159	CcSEcCtD
Naproxen—Vertigo—Doxorubicin—lung cancer	2.4e-05	0.000159	CcSEcCtD
Naproxen—Anorexia—Methotrexate—lung cancer	2.4e-05	0.000159	CcSEcCtD
Naproxen—Syncope—Doxorubicin—lung cancer	2.39e-05	0.000159	CcSEcCtD
Naproxen—Leukopenia—Doxorubicin—lung cancer	2.39e-05	0.000158	CcSEcCtD
Naproxen—Diarrhoea—Docetaxel—lung cancer	2.39e-05	0.000158	CcSEcCtD
Naproxen—Palpitations—Doxorubicin—lung cancer	2.36e-05	0.000156	CcSEcCtD
Naproxen—Hypotension—Methotrexate—lung cancer	2.35e-05	0.000156	CcSEcCtD
Naproxen—Loss of consciousness—Doxorubicin—lung cancer	2.35e-05	0.000155	CcSEcCtD
Naproxen—Cough—Doxorubicin—lung cancer	2.33e-05	0.000154	CcSEcCtD
Naproxen—PTGS2—lymph node—lung cancer	2.32e-05	0.012	CbGeAlD
Naproxen—Convulsion—Doxorubicin—lung cancer	2.31e-05	0.000153	CcSEcCtD
Naproxen—Dizziness—Docetaxel—lung cancer	2.31e-05	0.000153	CcSEcCtD
Naproxen—Hypertension—Doxorubicin—lung cancer	2.31e-05	0.000153	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Methotrexate—lung cancer	2.29e-05	0.000152	CcSEcCtD
Naproxen—Insomnia—Methotrexate—lung cancer	2.28e-05	0.000151	CcSEcCtD
Naproxen—Chest pain—Doxorubicin—lung cancer	2.27e-05	0.000151	CcSEcCtD
Naproxen—Arthralgia—Doxorubicin—lung cancer	2.27e-05	0.000151	CcSEcCtD
Naproxen—Myalgia—Doxorubicin—lung cancer	2.27e-05	0.000151	CcSEcCtD
Naproxen—Anxiety—Doxorubicin—lung cancer	2.27e-05	0.00015	CcSEcCtD
Naproxen—Paraesthesia—Methotrexate—lung cancer	2.26e-05	0.00015	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.26e-05	0.000149	CcSEcCtD
Naproxen—Discomfort—Doxorubicin—lung cancer	2.25e-05	0.000149	CcSEcCtD
Naproxen—Dyspnoea—Methotrexate—lung cancer	2.24e-05	0.000149	CcSEcCtD
Naproxen—Somnolence—Methotrexate—lung cancer	2.24e-05	0.000148	CcSEcCtD
Naproxen—Dry mouth—Doxorubicin—lung cancer	2.22e-05	0.000147	CcSEcCtD
Naproxen—Vomiting—Docetaxel—lung cancer	2.22e-05	0.000147	CcSEcCtD
Naproxen—Dyspepsia—Methotrexate—lung cancer	2.22e-05	0.000147	CcSEcCtD
Naproxen—Rash—Docetaxel—lung cancer	2.2e-05	0.000146	CcSEcCtD
Naproxen—Dermatitis—Docetaxel—lung cancer	2.2e-05	0.000146	CcSEcCtD
Naproxen—Confusional state—Doxorubicin—lung cancer	2.2e-05	0.000145	CcSEcCtD
Naproxen—Decreased appetite—Methotrexate—lung cancer	2.19e-05	0.000145	CcSEcCtD
Naproxen—Headache—Docetaxel—lung cancer	2.19e-05	0.000145	CcSEcCtD
Naproxen—Anaphylactic shock—Doxorubicin—lung cancer	2.18e-05	0.000144	CcSEcCtD
Naproxen—Oedema—Doxorubicin—lung cancer	2.18e-05	0.000144	CcSEcCtD
Naproxen—Gastrointestinal disorder—Methotrexate—lung cancer	2.17e-05	0.000144	CcSEcCtD
Naproxen—Fatigue—Methotrexate—lung cancer	2.17e-05	0.000144	CcSEcCtD
Naproxen—Infection—Doxorubicin—lung cancer	2.16e-05	0.000143	CcSEcCtD
Naproxen—Pain—Methotrexate—lung cancer	2.15e-05	0.000143	CcSEcCtD
Naproxen—Shock—Doxorubicin—lung cancer	2.14e-05	0.000142	CcSEcCtD
Naproxen—Nervous system disorder—Doxorubicin—lung cancer	2.14e-05	0.000142	CcSEcCtD
Naproxen—Thrombocytopenia—Doxorubicin—lung cancer	2.13e-05	0.000141	CcSEcCtD
Naproxen—Tachycardia—Doxorubicin—lung cancer	2.13e-05	0.000141	CcSEcCtD
Naproxen—Skin disorder—Doxorubicin—lung cancer	2.12e-05	0.00014	CcSEcCtD
Naproxen—Hyperhidrosis—Doxorubicin—lung cancer	2.11e-05	0.000139	CcSEcCtD
Naproxen—Anorexia—Doxorubicin—lung cancer	2.08e-05	0.000138	CcSEcCtD
Naproxen—Nausea—Docetaxel—lung cancer	2.07e-05	0.000137	CcSEcCtD
Naproxen—Feeling abnormal—Methotrexate—lung cancer	2.07e-05	0.000137	CcSEcCtD
Naproxen—Gastrointestinal pain—Methotrexate—lung cancer	2.06e-05	0.000136	CcSEcCtD
Naproxen—Hypotension—Doxorubicin—lung cancer	2.04e-05	0.000135	CcSEcCtD
Naproxen—Urticaria—Methotrexate—lung cancer	2e-05	0.000132	CcSEcCtD
Naproxen—Body temperature increased—Methotrexate—lung cancer	1.99e-05	0.000132	CcSEcCtD
Naproxen—Abdominal pain—Methotrexate—lung cancer	1.99e-05	0.000132	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Doxorubicin—lung cancer	1.99e-05	0.000131	CcSEcCtD
Naproxen—Insomnia—Doxorubicin—lung cancer	1.97e-05	0.000131	CcSEcCtD
Naproxen—Paraesthesia—Doxorubicin—lung cancer	1.96e-05	0.00013	CcSEcCtD
Naproxen—Dyspnoea—Doxorubicin—lung cancer	1.94e-05	0.000129	CcSEcCtD
Naproxen—Somnolence—Doxorubicin—lung cancer	1.94e-05	0.000128	CcSEcCtD
Naproxen—Dyspepsia—Doxorubicin—lung cancer	1.92e-05	0.000127	CcSEcCtD
Naproxen—Decreased appetite—Doxorubicin—lung cancer	1.89e-05	0.000125	CcSEcCtD
Naproxen—Gastrointestinal disorder—Doxorubicin—lung cancer	1.88e-05	0.000125	CcSEcCtD
Naproxen—Fatigue—Doxorubicin—lung cancer	1.88e-05	0.000124	CcSEcCtD
Naproxen—Pain—Doxorubicin—lung cancer	1.86e-05	0.000123	CcSEcCtD
Naproxen—Constipation—Doxorubicin—lung cancer	1.86e-05	0.000123	CcSEcCtD
Naproxen—Hypersensitivity—Methotrexate—lung cancer	1.85e-05	0.000123	CcSEcCtD
Naproxen—Asthenia—Methotrexate—lung cancer	1.81e-05	0.00012	CcSEcCtD
Naproxen—Feeling abnormal—Doxorubicin—lung cancer	1.8e-05	0.000119	CcSEcCtD
Naproxen—Gastrointestinal pain—Doxorubicin—lung cancer	1.78e-05	0.000118	CcSEcCtD
Naproxen—Pruritus—Methotrexate—lung cancer	1.78e-05	0.000118	CcSEcCtD
Naproxen—Urticaria—Doxorubicin—lung cancer	1.73e-05	0.000115	CcSEcCtD
Naproxen—Body temperature increased—Doxorubicin—lung cancer	1.72e-05	0.000114	CcSEcCtD
Naproxen—Abdominal pain—Doxorubicin—lung cancer	1.72e-05	0.000114	CcSEcCtD
Naproxen—Diarrhoea—Methotrexate—lung cancer	1.72e-05	0.000114	CcSEcCtD
Naproxen—Dizziness—Methotrexate—lung cancer	1.66e-05	0.00011	CcSEcCtD
Naproxen—Hypersensitivity—Doxorubicin—lung cancer	1.61e-05	0.000106	CcSEcCtD
Naproxen—Vomiting—Methotrexate—lung cancer	1.6e-05	0.000106	CcSEcCtD
Naproxen—Rash—Methotrexate—lung cancer	1.59e-05	0.000105	CcSEcCtD
Naproxen—Dermatitis—Methotrexate—lung cancer	1.59e-05	0.000105	CcSEcCtD
Naproxen—Headache—Methotrexate—lung cancer	1.58e-05	0.000104	CcSEcCtD
Naproxen—Asthenia—Doxorubicin—lung cancer	1.56e-05	0.000104	CcSEcCtD
Naproxen—Pruritus—Doxorubicin—lung cancer	1.54e-05	0.000102	CcSEcCtD
Naproxen—Nausea—Methotrexate—lung cancer	1.49e-05	9.9e-05	CcSEcCtD
Naproxen—Diarrhoea—Doxorubicin—lung cancer	1.49e-05	9.87e-05	CcSEcCtD
Naproxen—Dizziness—Doxorubicin—lung cancer	1.44e-05	9.54e-05	CcSEcCtD
Naproxen—Vomiting—Doxorubicin—lung cancer	1.39e-05	9.17e-05	CcSEcCtD
Naproxen—Rash—Doxorubicin—lung cancer	1.37e-05	9.1e-05	CcSEcCtD
Naproxen—Dermatitis—Doxorubicin—lung cancer	1.37e-05	9.09e-05	CcSEcCtD
Naproxen—Headache—Doxorubicin—lung cancer	1.37e-05	9.04e-05	CcSEcCtD
Naproxen—Nausea—Doxorubicin—lung cancer	1.29e-05	8.57e-05	CcSEcCtD
Naproxen—CYP1A2—Metabolism—UGT1A1—lung cancer	4.76e-06	5.73e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—lung cancer	4.75e-06	5.71e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP2E1—lung cancer	4.75e-06	5.71e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—lung cancer	4.74e-06	5.7e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—HPGDS—lung cancer	4.74e-06	5.7e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ENO2—lung cancer	4.74e-06	5.7e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP2E1—lung cancer	4.72e-06	5.68e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ALB—lung cancer	4.72e-06	5.67e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PPP2R1B—lung cancer	4.71e-06	5.66e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT3—lung cancer	4.7e-06	5.66e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CREBBP—lung cancer	4.7e-06	5.66e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NQO1—lung cancer	4.69e-06	5.64e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NRAS—lung cancer	4.69e-06	5.64e-05	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IL6—lung cancer	4.69e-06	5.64e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CAT—lung cancer	4.68e-06	5.63e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—NQO1—lung cancer	4.67e-06	5.61e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—EP300—lung cancer	4.65e-06	5.6e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—TERT—lung cancer	4.65e-06	5.59e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	4.65e-06	5.59e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL2—lung cancer	4.61e-06	5.54e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTT1—lung cancer	4.6e-06	5.53e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	4.6e-06	5.53e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GNG11—lung cancer	4.59e-06	5.52e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	4.57e-06	5.5e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	4.57e-06	5.49e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ABCB1—lung cancer	4.55e-06	5.48e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	4.55e-06	5.48e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GCLC—lung cancer	4.54e-06	5.46e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP2A6—lung cancer	4.54e-06	5.46e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—APOA1—lung cancer	4.53e-06	5.45e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	4.53e-06	5.44e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	4.53e-06	5.44e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—FGFR1—lung cancer	4.52e-06	5.43e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK3—lung cancer	4.49e-06	5.4e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—TYMS—lung cancer	4.47e-06	5.38e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CD—lung cancer	4.46e-06	5.36e-05	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—RAF1—lung cancer	4.45e-06	5.35e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HIF1A—lung cancer	4.45e-06	5.35e-05	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PIK3CA—lung cancer	4.44e-06	5.34e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTM1—lung cancer	4.42e-06	5.32e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ALB—lung cancer	4.4e-06	5.29e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALDOA—lung cancer	4.37e-06	5.26e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—lung cancer	4.37e-06	5.26e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.34e-06	5.22e-05	CbGpPWpGaD
Naproxen—AKR1C3—Disease—AKT1—lung cancer	4.33e-06	5.21e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ENO1—lung cancer	4.31e-06	5.18e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—APOA1—lung cancer	4.29e-06	5.16e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	4.29e-06	5.16e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—lung cancer	4.28e-06	5.14e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NCOA3—lung cancer	4.25e-06	5.1e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	4.24e-06	5.09e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—STK11—lung cancer	4.23e-06	5.09e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—STK11—lung cancer	4.21e-06	5.06e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP1A1—lung cancer	4.19e-06	5.04e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	4.17e-06	5.02e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CB—lung cancer	4.17e-06	5.01e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ERCC2—lung cancer	4.16e-06	5e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—EP300—lung cancer	4.14e-06	4.97e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CG—lung cancer	4.14e-06	4.97e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTEN—lung cancer	4.13e-06	4.97e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCG2—lung cancer	4.13e-06	4.97e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ADCY1—lung cancer	4.13e-06	4.97e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—lung cancer	4.13e-06	4.96e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ENO2—lung cancer	4.05e-06	4.87e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HPGDS—lung cancer	4.05e-06	4.87e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KRAS—lung cancer	4.04e-06	4.86e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PPP2R1B—lung cancer	4.02e-06	4.84e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SRC—lung cancer	4.02e-06	4.84e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.97e-06	4.78e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	3.97e-06	4.77e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.95e-06	4.75e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—EP300—lung cancer	3.94e-06	4.74e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—POMC—lung cancer	3.94e-06	4.73e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTT1—lung cancer	3.93e-06	4.72e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—KIT—lung cancer	3.92e-06	4.71e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—APC—lung cancer	3.92e-06	4.71e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—lung cancer	3.92e-06	4.71e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTP1—lung cancer	3.91e-06	4.71e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTP1—lung cancer	3.89e-06	4.68e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CB—lung cancer	3.89e-06	4.67e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GCLC—lung cancer	3.88e-06	4.67e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP2A6—lung cancer	3.88e-06	4.67e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGF—lung cancer	3.87e-06	4.66e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NRAS—lung cancer	3.87e-06	4.65e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	3.87e-06	4.65e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP2E1—lung cancer	3.86e-06	4.65e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—lung cancer	3.85e-06	4.63e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CREBBP—lung cancer	3.83e-06	4.61e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NQO1—lung cancer	3.82e-06	4.59e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CAT—lung cancer	3.81e-06	4.58e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CAT—lung cancer	3.79e-06	4.55e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.79e-06	4.55e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.77e-06	4.53e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.74e-06	4.5e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CA—lung cancer	3.71e-06	4.46e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.71e-06	4.46e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK3—lung cancer	3.71e-06	4.46e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ABCB1—lung cancer	3.71e-06	4.46e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—BRAF—lung cancer	3.68e-06	4.43e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ABCB1—lung cancer	3.68e-06	4.43e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ENO1—lung cancer	3.68e-06	4.43e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	3.67e-06	4.41e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6R—lung cancer	3.64e-06	4.38e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TYMS—lung cancer	3.64e-06	4.38e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CD—lung cancer	3.64e-06	4.37e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CREBBP—lung cancer	3.63e-06	4.37e-05	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AKT1—lung cancer	3.63e-06	4.36e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	3.62e-06	4.35e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—TYMS—lung cancer	3.62e-06	4.35e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTEN—lung cancer	3.6e-06	4.33e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTM1—lung cancer	3.6e-06	4.33e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—APOA1—lung cancer	3.6e-06	4.32e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—lung cancer	3.59e-06	4.32e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ALB—lung cancer	3.59e-06	4.32e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTM1—lung cancer	3.58e-06	4.3e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAP2K1—lung cancer	3.47e-06	4.17e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CD—lung cancer	3.45e-06	4.14e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—STK11—lung cancer	3.44e-06	4.14e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.44e-06	4.14e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HRAS—lung cancer	3.43e-06	4.13e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—EP300—lung cancer	3.43e-06	4.13e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP1A1—lung cancer	3.41e-06	4.1e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP1A1—lung cancer	3.39e-06	4.08e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ERCC2—lung cancer	3.38e-06	4.07e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ERCC2—lung cancer	3.36e-06	4.04e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTEN—lung cancer	3.36e-06	4.04e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KRAS—lung cancer	3.33e-06	4.01e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP2E1—lung cancer	3.3e-06	3.97e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL6—lung cancer	3.29e-06	3.95e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CG—lung cancer	3.28e-06	3.95e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NQO1—lung cancer	3.26e-06	3.93e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.23e-06	3.89e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—EP300—lung cancer	3.2e-06	3.85e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	3.2e-06	3.84e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTP1—lung cancer	3.19e-06	3.83e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CB—lung cancer	3.17e-06	3.81e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	3.17e-06	3.81e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—lung cancer	3.14e-06	3.78e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—POMC—lung cancer	3.12e-06	3.76e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CAT—lung cancer	3.1e-06	3.73e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MDM2—lung cancer	3.09e-06	3.71e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.08e-06	3.71e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—RAF1—lung cancer	3.08e-06	3.7e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CA—lung cancer	3.06e-06	3.68e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CREBBP—lung cancer	3.04e-06	3.66e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB2—lung cancer	3.04e-06	3.66e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AKT1—lung cancer	3.03e-06	3.65e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ABCB1—lung cancer	3.02e-06	3.63e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MTOR—lung cancer	3e-06	3.61e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CB—lung cancer	3e-06	3.61e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD4—lung cancer	3e-06	3.61e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TYMS—lung cancer	2.96e-06	3.56e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—lung cancer	2.96e-06	3.56e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—STK11—lung cancer	2.94e-06	3.54e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTM1—lung cancer	2.93e-06	3.52e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—APOA1—lung cancer	2.93e-06	3.52e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CA—lung cancer	2.92e-06	3.51e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—APOA1—lung cancer	2.91e-06	3.5e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CD—lung cancer	2.89e-06	3.47e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALB—lung cancer	2.85e-06	3.43e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HRAS—lung cancer	2.83e-06	3.4e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.8e-06	3.37e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.79e-06	3.35e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP1A1—lung cancer	2.78e-06	3.34e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.76e-06	3.32e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ERCC2—lung cancer	2.75e-06	3.31e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTEN—lung cancer	2.74e-06	3.29e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTP1—lung cancer	2.72e-06	3.27e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CG—lung cancer	2.67e-06	3.21e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CG—lung cancer	2.66e-06	3.19e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CAT—lung cancer	2.65e-06	3.19e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.63e-06	3.17e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—EP300—lung cancer	2.61e-06	3.14e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1A—lung cancer	2.6e-06	3.13e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTEN—lung cancer	2.6e-06	3.12e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCB1—lung cancer	2.58e-06	3.1e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—POMC—lung cancer	2.54e-06	3.06e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CA—lung cancer	2.54e-06	3.05e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TYMS—lung cancer	2.53e-06	3.04e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—POMC—lung cancer	2.53e-06	3.04e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CB—lung cancer	2.52e-06	3.02e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTM1—lung cancer	2.5e-06	3.01e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—AKT1—lung cancer	2.5e-06	3.01e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CREBBP—lung cancer	2.48e-06	2.98e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EP300—lung cancer	2.48e-06	2.98e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CREBBP—lung cancer	2.46e-06	2.96e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—SRC—lung cancer	2.41e-06	2.89e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKT1—lung cancer	2.38e-06	2.86e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APOA1—lung cancer	2.38e-06	2.86e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP1A1—lung cancer	2.37e-06	2.85e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CA—lung cancer	2.37e-06	2.85e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ERCC2—lung cancer	2.35e-06	2.83e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CD—lung cancer	2.35e-06	2.82e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CD—lung cancer	2.33e-06	2.81e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—lung cancer	2.32e-06	2.79e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALB—lung cancer	2.32e-06	2.79e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NRAS—lung cancer	2.32e-06	2.78e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.28e-06	2.74e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK3—lung cancer	2.22e-06	2.67e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CG—lung cancer	2.17e-06	2.61e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTEN—lung cancer	2.17e-06	2.61e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—lung cancer	2.16e-06	2.59e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—lung cancer	2.11e-06	2.54e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKT1—lung cancer	2.07e-06	2.49e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—EP300—lung cancer	2.07e-06	2.49e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—POMC—lung cancer	2.07e-06	2.49e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CB—lung cancer	2.05e-06	2.46e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CB—lung cancer	2.04e-06	2.45e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APOA1—lung cancer	2.03e-06	2.45e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—lung cancer	2.03e-06	2.44e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—lung cancer	2.02e-06	2.42e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CREBBP—lung cancer	2.02e-06	2.42e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—KRAS—lung cancer	1.99e-06	2.4e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.95e-06	2.34e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKT1—lung cancer	1.94e-06	2.33e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CA—lung cancer	1.93e-06	2.32e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CD—lung cancer	1.91e-06	2.3e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALB—lung cancer	1.89e-06	2.27e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CG—lung cancer	1.86e-06	2.23e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CA—lung cancer	1.83e-06	2.2e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTEN—lung cancer	1.77e-06	2.13e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—POMC—lung cancer	1.77e-06	2.13e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTEN—lung cancer	1.76e-06	2.11e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CREBBP—lung cancer	1.72e-06	2.07e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HRAS—lung cancer	1.69e-06	2.04e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—EP300—lung cancer	1.69e-06	2.03e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—EP300—lung cancer	1.68e-06	2.02e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CB—lung cancer	1.67e-06	2e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—lung cancer	1.65e-06	1.98e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CD—lung cancer	1.63e-06	1.96e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6—lung cancer	1.62e-06	1.95e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALB—lung cancer	1.61e-06	1.94e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKT1—lung cancer	1.58e-06	1.9e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CA—lung cancer	1.53e-06	1.84e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT1—lung cancer	1.5e-06	1.8e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTEN—lung cancer	1.44e-06	1.73e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CB—lung cancer	1.42e-06	1.71e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—lung cancer	1.41e-06	1.7e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—EP300—lung cancer	1.37e-06	1.65e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKT1—lung cancer	1.25e-06	1.51e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CA—lung cancer	1.25e-06	1.5e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CA—lung cancer	1.24e-06	1.49e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTEN—lung cancer	1.23e-06	1.48e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—EP300—lung cancer	1.17e-06	1.41e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKT1—lung cancer	1.02e-06	1.23e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CA—lung cancer	1.02e-06	1.22e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKT1—lung cancer	1.01e-06	1.22e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CA—lung cancer	8.68e-07	1.04e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKT1—lung cancer	8.3e-07	9.98e-06	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKT1—lung cancer	7.09e-07	8.52e-06	CbGpPWpGaD
